PDCD1 and colorectal carcinoma: First, we will illustrate clinically approved anti-PD-1/PD-L1 therapies as a promising treatment option for immunotherapy-sensitive CRC and microsatellite instable CRC (MSI-H/dMMR) and briefly discuss their resistance development to anti-PD-1/PDL-1.